December 18, 2023 /3BL/ – Qurate Retail Group, which comprises six leading retail brands – QVC®, HSN®, Ballard Designs®, Frontgate®, Garnet Hill® and Grandin Road® – has been recognized on Newsweek’s list of America’s Most Responsible Companies 2024. The world leader in video commerce (“vCommerce”) ranked second out of 25 in the retail industry and earned a spot among the top 125 companies overall. This accolade is presented by Newsweek in collaboration with Statista Inc., a renowned statistics portal and industry ranking provider.

America’s Most Responsible Companies recognizes the top 600 most responsible companies in the United States, spanning 14 industries. The ranking focuses on a holistic view of corporate responsibility that considers all three pillars of ESG: Environment, Social, and Corporate Governance. The analysis is based on two metrics:

KPI research: The KPI research formed the first part of the detailed analysis. Over 30 KPIs have been researched for the top 2,000 public companies by revenue with headquarters in the USA.Public survey: The survey was the second part of the detailed analysis to evaluate the companies’ CSR reputation. 17,000 US residents were surveyed. Respondents were asked to select companies familiar to them and then to evaluate the company’s CSR performance in general and in the three subdimensions: social, environmental and governance.

In September 2023, Qurate Retail Group released its third annual Corporate Responsibility Report, where it announced significant advancements in its efforts to protect the environment, foster empowerment and belonging, and curate product responsibly. Highlights from the report include a 26% reduction in Scope 1 and 2 emissions, surpassing total charitable giving goals three years early and the implementation of traceability audits to enhance supply chain visibility. The report underscores Qurate Retail Group’s dedication to sustainability, philanthropy and fostering an inclusive business for the benefit of all stakeholders – including customers, team members, vendors, community members, and shareholders.

To learn more about Qurate Retail Group’s commitment to Corporate Responsibility, visit: www.qurateretailgroup.com/lp/corporate-responsibility/

Schneider Electric

Way back in 1982, I started my career when I became a trainee electrician at the age of 16. The talk at the time was all about acid rain and the ozone layer. The terms “global warming” and “climate change” were only just starting to appear on the public radar. The first-ever COP climate change conference (Berlin, 1995) was still several years away.

Fast-forward to 2023. In the time it’s taken me to go from trainee to CEO of a global leader in energy management and automation, those early hints of global warming have swelled into outright climate crisis. Successive COPs (number 28 is happening soon) have resulted in ambitious decarbonization targets and policy initiatives around the world.

But governments can’t do it all alone. The corporate sector needs to be part of the action, and there’s a lot more companies can do to get us towards net-zero emissions faster.

The good news is that in spite of – or perhaps because of – the geopolitical, economic and energy-market turmoil of recent years, the business world is increasingly making commitments to sustainability and decarbonization.

As of now, some 3,900 companies worldwide have set emissions-reduction targets validated by the Science Based Targets initiative (SBTi). And according to the Net Zero Tracker, 929 of the 2,000 largest publicly-traded companies in the world had net-zero commitments in place as of mid-2023. That’s more than double the number of two years earlier.

But many businesses have yet to set decarbonization goals or deliver as much action as they could.

Why is that? I believe the hold-up is partly due to still-insufficient awareness of the solutions at our collective disposal and of the benefits of action.

Misconception number one is that decarbonization is entirely about increasing the use of solar, wind and tidal power. As important as supplying more clean, renewable energy, however, is tackling the demand side and optimizing how energy is consumed. And while energy efficiency is starting to get more attention, the role it plays on the path to net zero is often overlooked and under-appreciated.

That’s despite the fact that plenty of powerful solutions for energy efficiency already exist. Automation software that optimizes processes and energy usage in industrial sites and value chains, for example. Or digitally-enabled heating and cooling systems that identify and reduce energy waste in homes and commercial buildings. And electric heat pumps and EVs, which are cleaner and far more energy efficient than fossil-fueled technologies.

The second misconception is that such technologies are not particularly effective and that they yield a low return on investment. In fact, the good news is that both effectiveness and ROI are often larger than many assume.

Take the findings of research we conducted with the global design firm WSP. These showed that installing digital building and power management solutions in existing office buildings could reduce their operational carbon emissions by up to 42% with a payback period of less than three years. What’s more, replacing fossil fuel-powered heating technologies with electric-powered alternatives, and installing a microgrid with local renewable energy sources, can achieve an additional 28% reduction in operational carbon emissions.

Yes, policy action is key to setting frameworks and incentivizing action. And the Alliance of CEO Climate Leaders recently called for more to be done to streamline permitting processes, harmonize climate disclosure standards, and phase out fossil fuel subsidies, among other things.

But rather than wait for the policy environment to keep improving further, the corporate sector can and must do more, faster, now.

Even companies that are not directly involved in creating and selling decarbonization and climate solutions can reduce emissions and raw materials usage both in their own operations and within their supply and distribution chains.

They can contribute to the public debate, by sharing research and expertise. They can support communities through corporate citizenship programs, or through training initiatives that address the shortage of skills in the digital, electrification and clean energy sectors, particularly in remote or underdeveloped parts of the world, to ensure the energy transition is fair and inclusive.

And they can provide the commercial acumen and marketing expertise (and sometimes seed capital or financial backing) that’s needed to take innovations from the drawing board to fruition, and to market.

All this requires effort and financial commitment. But it’s time to recognize holistic, cooperative and multi-faceted corporate sustainability action as not just a must-do imposed by regulators, but as a business and job-creation opportunity that can lower emissions and costs faster than many realize.

Take it from a trainee-electrician-turned-software-engineer-turned-company-CEO: there are ample electrification, digital, automation and other technologies at our disposal today. There’s both a moral and a business case for deploying them at much greater scale and speed. And the cost of inaction would ultimately be far greater than the cost of action.

Schneider Electric

Way back in 1982, I started my career when I became a trainee electrician at the age of 16. The talk at the time was all about acid rain and the ozone layer. The terms “global warming” and “climate change” were only just starting to appear on the public radar. The first-ever COP climate change conference (Berlin, 1995) was still several years away.

Fast-forward to 2023. In the time it’s taken me to go from trainee to CEO of a global leader in energy management and automation, those early hints of global warming have swelled into outright climate crisis. Successive COPs (number 28 is happening soon) have resulted in ambitious decarbonization targets and policy initiatives around the world.

But governments can’t do it all alone. The corporate sector needs to be part of the action, and there’s a lot more companies can do to get us towards net-zero emissions faster.

The good news is that in spite of – or perhaps because of – the geopolitical, economic and energy-market turmoil of recent years, the business world is increasingly making commitments to sustainability and decarbonization.

As of now, some 3,900 companies worldwide have set emissions-reduction targets validated by the Science Based Targets initiative (SBTi). And according to the Net Zero Tracker, 929 of the 2,000 largest publicly-traded companies in the world had net-zero commitments in place as of mid-2023. That’s more than double the number of two years earlier.

But many businesses have yet to set decarbonization goals or deliver as much action as they could.

Why is that? I believe the hold-up is partly due to still-insufficient awareness of the solutions at our collective disposal and of the benefits of action.

Misconception number one is that decarbonization is entirely about increasing the use of solar, wind and tidal power. As important as supplying more clean, renewable energy, however, is tackling the demand side and optimizing how energy is consumed. And while energy efficiency is starting to get more attention, the role it plays on the path to net zero is often overlooked and under-appreciated.

That’s despite the fact that plenty of powerful solutions for energy efficiency already exist. Automation software that optimizes processes and energy usage in industrial sites and value chains, for example. Or digitally-enabled heating and cooling systems that identify and reduce energy waste in homes and commercial buildings. And electric heat pumps and EVs, which are cleaner and far more energy efficient than fossil-fueled technologies.

The second misconception is that such technologies are not particularly effective and that they yield a low return on investment. In fact, the good news is that both effectiveness and ROI are often larger than many assume.

Take the findings of research we conducted with the global design firm WSP. These showed that installing digital building and power management solutions in existing office buildings could reduce their operational carbon emissions by up to 42% with a payback period of less than three years. What’s more, replacing fossil fuel-powered heating technologies with electric-powered alternatives, and installing a microgrid with local renewable energy sources, can achieve an additional 28% reduction in operational carbon emissions.

Yes, policy action is key to setting frameworks and incentivizing action. And the Alliance of CEO Climate Leaders recently called for more to be done to streamline permitting processes, harmonize climate disclosure standards, and phase out fossil fuel subsidies, among other things.

But rather than wait for the policy environment to keep improving further, the corporate sector can and must do more, faster, now.

Even companies that are not directly involved in creating and selling decarbonization and climate solutions can reduce emissions and raw materials usage both in their own operations and within their supply and distribution chains.

They can contribute to the public debate, by sharing research and expertise. They can support communities through corporate citizenship programs, or through training initiatives that address the shortage of skills in the digital, electrification and clean energy sectors, particularly in remote or underdeveloped parts of the world, to ensure the energy transition is fair and inclusive.

And they can provide the commercial acumen and marketing expertise (and sometimes seed capital or financial backing) that’s needed to take innovations from the drawing board to fruition, and to market.

All this requires effort and financial commitment. But it’s time to recognize holistic, cooperative and multi-faceted corporate sustainability action as not just a must-do imposed by regulators, but as a business and job-creation opportunity that can lower emissions and costs faster than many realize.

Take it from a trainee-electrician-turned-software-engineer-turned-company-CEO: there are ample electrification, digital, automation and other technologies at our disposal today. There’s both a moral and a business case for deploying them at much greater scale and speed. And the cost of inaction would ultimately be far greater than the cost of action.

Diversity, equity, and inclusion (DEI) are not just words but values that are exemplified through our One Cadence—One Team culture and the importance of sustaining it as we learn from diverse perspectives.

“Alone we can do so little; together we can do so much.“ – Helen Keller

“None of us, including me, ever do great things. But we can all do small things with great love, and together we can do something wonderful.“ – Mother Teresa

Cadence Women Conference Global

I was honored to participate in our very first global Cadence Women Conference (CWC), which took place in sunny San Diego, California, and brought together 250 attendees from 15 different countries. The program for this year’s conference revolved around the theme of #bettertogether#, emphasizing that we are not just the sum of our parts but that our success is multiplied when we lift, support, and amplify each other.

This event showcased keynote speakers from academia and industry, as well as workshops, panels, networking, and mentorship. Additionally, it featured our signature “Voice” track, where employees shared their thoughts on workplace improvements.

CWC Recap Around the Globe

To continue the energy and extend the learnings to more people in our community, I worked with a passionate global team of volunteers to host in-person recap events around the globe. This included San Jose, Austin, Burlington, and Belo Horizonte in North and South America; Cork, Dublin, and Bracknell in Europe; Noida and Bangalore in India; and Seoul, Shanghai, Hsinchu, Beijing, Nanjing, and Singapore in Asia.

We had a blast at the recap events, where we got to hear from attendees about their experiences and insights from the global conference. It was even better because some amazing allies joined us for the learning and discussion sessions. At every site, we had featured agendas planned, including awesome summaries of the mentoring sessions, workshops, Voice, and clips from our inspiring speakers: Jodi Shelton, CEO of the Global Semiconductor Alliance; ML Krakauer, chair of the board at Cadence; and Asu Ozdaglar, MathWorks professor and department head of Electrical Engineering and Computer Science at MIT. We also included fun and community-giving activities. 16 site events created great opportunities for women and their allies to learn, network, and celebrate. We’re thrilled to have had such an incredible experience!

Do One Thing for Yourself and One Thing for Others

The global recap events demonstrated Cadence’s “#bettertogether# spirit by following the philosophy of “do one thing for yourself and do one thing for others.” This is something that our executive sponsor, Yoon Kim, always asks of attendees. Here are some highlights.

Makeup Kit Packing: We collaborated with the Cadence Giving Foundation and volunteered with Dress for Success San Jose to assemble makeup kits and write notes of encouragement, which will be given to Dress for Success clients to help them feel confident for job interviews and new jobs.

Giving Back to Community: We received donations from across the Korea site to purchase goods, and our attendees worked together to package 42 sets of hopeFULL hygiene kits for teenage girls in the community. We spread joy through giving and inspire others to do the same together!

Aromatherapy DIY Station: In our fast-paced, technology-driven world, it can be easy to neglect yourself. Aromatherapy is the practice of using essential oils for therapeutic benefit. The U.S. attendees enjoyed creating an aromatherapy kit to take home for themselves and their loved ones.

CWC Post-it Wall: At the India site, a wonderful idea was introduced to reflect on one’s actions. The idea was that everyone should write on colored post-its—green was for what you did for the community (C), orange was for what you did for yourself (W for “we”), and pink was for what you did for Cadence (C).

Conclusion

I cannot express enough how thankful I am to all the wonderful volunteers and participants who made this series of events a huge success! The dedication and passion demonstrated by everyone involved is truly inspiring. Cadence is taking great strides towards empowering women through initiatives such as CWC, post-event activities, and many more local events. I am confident that these efforts will make a significant impact in creating a stronger and more supportive community for women at Cadence. This is only the beginning, and I am excited to see what the future holds for our amazing women’s community!

Diversity, equity, and inclusion (DEI) are not just words but values that are exemplified through our One Cadence—One Team culture and the importance of sustaining it as we learn from diverse perspectives.

“Alone we can do so little; together we can do so much.“ – Helen Keller

“None of us, including me, ever do great things. But we can all do small things with great love, and together we can do something wonderful.“ – Mother Teresa

Cadence Women Conference Global

I was honored to participate in our very first global Cadence Women Conference (CWC), which took place in sunny San Diego, California, and brought together 250 attendees from 15 different countries. The program for this year’s conference revolved around the theme of #bettertogether#, emphasizing that we are not just the sum of our parts but that our success is multiplied when we lift, support, and amplify each other.

This event showcased keynote speakers from academia and industry, as well as workshops, panels, networking, and mentorship. Additionally, it featured our signature “Voice” track, where employees shared their thoughts on workplace improvements.

CWC Recap Around the Globe

To continue the energy and extend the learnings to more people in our community, I worked with a passionate global team of volunteers to host in-person recap events around the globe. This included San Jose, Austin, Burlington, and Belo Horizonte in North and South America; Cork, Dublin, and Bracknell in Europe; Noida and Bangalore in India; and Seoul, Shanghai, Hsinchu, Beijing, Nanjing, and Singapore in Asia.

We had a blast at the recap events, where we got to hear from attendees about their experiences and insights from the global conference. It was even better because some amazing allies joined us for the learning and discussion sessions. At every site, we had featured agendas planned, including awesome summaries of the mentoring sessions, workshops, Voice, and clips from our inspiring speakers: Jodi Shelton, CEO of the Global Semiconductor Alliance; ML Krakauer, chair of the board at Cadence; and Asu Ozdaglar, MathWorks professor and department head of Electrical Engineering and Computer Science at MIT. We also included fun and community-giving activities. 16 site events created great opportunities for women and their allies to learn, network, and celebrate. We’re thrilled to have had such an incredible experience!

Do One Thing for Yourself and One Thing for Others

The global recap events demonstrated Cadence’s “#bettertogether# spirit by following the philosophy of “do one thing for yourself and do one thing for others.” This is something that our executive sponsor, Yoon Kim, always asks of attendees. Here are some highlights.

Makeup Kit Packing: We collaborated with the Cadence Giving Foundation and volunteered with Dress for Success San Jose to assemble makeup kits and write notes of encouragement, which will be given to Dress for Success clients to help them feel confident for job interviews and new jobs.

Giving Back to Community: We received donations from across the Korea site to purchase goods, and our attendees worked together to package 42 sets of hopeFULL hygiene kits for teenage girls in the community. We spread joy through giving and inspire others to do the same together!

Aromatherapy DIY Station: In our fast-paced, technology-driven world, it can be easy to neglect yourself. Aromatherapy is the practice of using essential oils for therapeutic benefit. The U.S. attendees enjoyed creating an aromatherapy kit to take home for themselves and their loved ones.

CWC Post-it Wall: At the India site, a wonderful idea was introduced to reflect on one’s actions. The idea was that everyone should write on colored post-its—green was for what you did for the community (C), orange was for what you did for yourself (W for “we”), and pink was for what you did for Cadence (C).

Conclusion

I cannot express enough how thankful I am to all the wonderful volunteers and participants who made this series of events a huge success! The dedication and passion demonstrated by everyone involved is truly inspiring. Cadence is taking great strides towards empowering women through initiatives such as CWC, post-event activities, and many more local events. I am confident that these efforts will make a significant impact in creating a stronger and more supportive community for women at Cadence. This is only the beginning, and I am excited to see what the future holds for our amazing women’s community!

Originally published in Dow’s 2022 INtersections Progress Report

Two key initiatives were launched in 2022 to reduce unplanned events, in particular, Process Safety Containment Events (PSCEs). Both provided global guidance with the flexibility to tailor at the site and plant level.

PSCE REDUCTION EFFORT

In April 2022, Operations and EH&S leadership implemented a new PSCE Reduction Effort. This global effort was designed so that on-site teams identified and addressed specific needs and challenges. Team members
– Dow and contractor – were encouraged to identify potentially unsafe scenarios and mitigations to prevent the occurrence of PSCEs. Leaders increased the amount of time spent in the field with their teams to help set and maintain workplace expectations. This tailored approach allowed us to focus on the most critical opportunities and make a quick impact.

This effort was critical to make a quick impact and it was complemented later in the year with the launch of a new campaign: “Prevent. Protect. Respond.” This campaign emphasizes executing fundamentals with excellence and is designed so that facilities can individually customize the focus to address their greatest needs.

UNPLANNED EVENT REDUCTION SUMMIT

Leaders from around the world who work in EHS&S and Operations gathered to discuss and address unplanned events globally, with an emphasis on one of our most challenged regions – the United States and Canada. The global team identified four key areas of focus and teams accountable for progress in each area:

“Staff to win” by ensuring optimal people resources and expertise at challenged sites and facilitiesImplement improvements to ensure equipment safety and reliability through fixed-asset preventive maintenanceEstablish targets based on the severity of consequence in order to guide corrective actions and prioritize resourcesContinue to use technology to minimize the risk of unplanned events

Read more.

Originally published in Dow’s 2022 INtersections Progress Report

Two key initiatives were launched in 2022 to reduce unplanned events, in particular, Process Safety Containment Events (PSCEs). Both provided global guidance with the flexibility to tailor at the site and plant level.

PSCE REDUCTION EFFORT

In April 2022, Operations and EH&S leadership implemented a new PSCE Reduction Effort. This global effort was designed so that on-site teams identified and addressed specific needs and challenges. Team members
– Dow and contractor – were encouraged to identify potentially unsafe scenarios and mitigations to prevent the occurrence of PSCEs. Leaders increased the amount of time spent in the field with their teams to help set and maintain workplace expectations. This tailored approach allowed us to focus on the most critical opportunities and make a quick impact.

This effort was critical to make a quick impact and it was complemented later in the year with the launch of a new campaign: “Prevent. Protect. Respond.” This campaign emphasizes executing fundamentals with excellence and is designed so that facilities can individually customize the focus to address their greatest needs.

UNPLANNED EVENT REDUCTION SUMMIT

Leaders from around the world who work in EHS&S and Operations gathered to discuss and address unplanned events globally, with an emphasis on one of our most challenged regions – the United States and Canada. The global team identified four key areas of focus and teams accountable for progress in each area:

“Staff to win” by ensuring optimal people resources and expertise at challenged sites and facilitiesImplement improvements to ensure equipment safety and reliability through fixed-asset preventive maintenanceEstablish targets based on the severity of consequence in order to guide corrective actions and prioritize resourcesContinue to use technology to minimize the risk of unplanned events

Read more.

Originally published in Alkermes September 2023 Corporate Responsibility Report

Ethics and Compliance

Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in the markets in which we operate and to maintaining a strong culture of compliance.

Our focus on compliance applies to all aspects of our business, beginning with preclinical research and continuing through clinical trials, manufacturing and commercialization. This focus on compliance helps to build trust with healthcare professionals, institutional purchasers, relevant government agencies and the public at large.

Compliance is a responsibility shared by all employees across all levels of the Company. We expect each employee to take an active role in supporting our culture of compliance and to perform all activities and conduct all interactions with integrity and in accordance with the highest ethical standards.

Our commitment to compliance is embodied in our comprehensive compliance program which is built on the following core elements:

Written policies and procedures that address the compliance risk areas relevant to pharmaceutical manufacturers, including those identified in the guidance of the Office of Inspector General of the U.S. Department of Health & Human Services (HHS) and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals.The Company’s Chief Compliance Officer oversees our compliance program and reports directly to the Company’s CEO. The Company’s Corporate Compliance Committee helps oversee the Company’s compliance program and assists with identifying any compliance issues that may need to be brought to the attention of the Board.Alkermes conducts extensive training and education programs for all employees that begin with new hire training and include regular, ongoing training on topics, processes and policies relevant to their positions.Alkermes has established and continues to foster a culture of compliance that maintains effective lines of communication and encourages all employees to seek guidance on ethical or legal issues as they arise. This culture of compliance is further supported by a policy obligating employees to report possible compliance violations and a strong anti-retaliation policy (discussed below) that protects personnel who report issues in good faith.Regular monitoring and auditing of the compliance program enables Alkermes to detect and prevent potential non-compliance.The Company’s policies and training ensure that all employees, including management, are informed of the consequences of failing to adhere to our compliance policies.Our compliance program is designed to promptly respond to and address, through corrective action, any detected instances of non-compliance.

Code of Conduct

Our Code of Business Conduct and Ethics (Code of Conduct) applies to all employees, officers and directors of the Company. A current copy of the Code of Conduct is available on the Corporate Governance page of the Investors section of our website.

Among other things, the Code of Conduct requires:

Honest and ethical conduct by employees, officers and directors of the Company, including the ethical handling of actual, potential or apparent conflicts of interest;Full, fair and understandable disclosure of the Company’s activities in reports filed with the SEC and in the Company’s other public communications; andPrompt internal reporting of any violations of the Code of Conduct to a supervisor, the Company’s Chief Legal Officer or the Company’s Chief Compliance Officer (which role is currently held by the Company’s Chief Legal Officer).

The Code of Conduct also requires compliance with all applicable laws, rules and regulations including, but not limited to, those guiding our interactions with government officials and health care providers. In this context, the Code of Conduct expressly prohibits any bribes, kickbacks or other improper payments, transfers or receipts.

Our employees are obligated to raise concerns about any violations of our Code of Conduct or any other ethics or conduct violations with their supervisor, the Company’s Chief Legal Officer or Chief Compliance Officer, the Audit and Risk Committee of the Board and/or the Nominating and Corporate Governance Committee of the Board or through the Company’s Corporate Governance hotline set forth in the Company’s Procedures for Reporting Financial and Compliance Matters; No Retaliation Policy (Whistleblower Policy). A current copy of the Whistleblower Policy is available on the Corporate Governance page of the Investors section of our website.

Responsible Research 

Clinical Trials

As a patient-focused organization, we value the patients who choose to participate in clinical trials and maintain policies, procedures and practices that are respectful of each study participant and designed to protect their health, safety and well-being. We ensure that our clinical programs comply with the laws and regulations of the jurisdictions where we conduct clinical research, including appropriate informed consent processes, ongoing assessment of patient safety and timely reporting of adverse events, accurate collection and integrity of data and respect for patient confidentiality and privacy.

Ethical Treatment of Animals

Alkermes is committed to the ethical and responsible treatment of animals involved in the Company’s research and development programs. We follow defined practices and standards for the care, welfare and treatment of research animals, as monitored by our Institutional Animal Care and Use Committee; and conduct all animal research in compliance with applicable local, national or international laws such as those set forth in the National Research Council’s Guide for the Care and Use of Laboratory Animals. We also require – through inclusion of relevant provisions in our contractual agreements – that the CROs, academic institutions and animal vendors with whom we engage commit to adherence to these same standards.

Responsible Manufacturing: Product Quality and Safety

Alkermes has robust policies and procedures in place to promote safe and sustainable research, development, manufacture and commercialization of products. We are committed to meeting our manufacturing objectives reliably and responsibly through the establishment and maintenance of a safe, sustainable and ethical supply chain.

Product Quality

The Alkermes Quality Management System (QMS) is a comprehensive program designed to ensure that products manufactured, stored, tested or distributed by Alkermes consistently meet applicable product specifications, safety and efficacy standards, GxP (as defined below) “good practice” quality guidelines and regulations, and regulatory requirements. The QMS is a combination of multiple wellintegrated components, covering the entire lifecycle of the products that we manufacture from development to commercialization and the full supply chain associated with each stage in a product’s manufacture.

Our QMS is designed to ensure compliance with applicable provisions of the U.S. Code of Federal Regulations, ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guidance, the European Commission Directives relating to medicinal products for human use and all aspects of “good practice” quality guidelines and regulations (known collectively as GxP), in each case in line with current industry standards.

GxP includes Good Clinical Practice (GCP) regulations, which govern the conduct of clinical trials, Good Manufacturing Practice (GMP) regulations, which govern the manufacture of products, and Good Laboratory Practice (GLP) regulations, which govern the testing of materials in accordance with applicable regulations. We also adhere to applicable quality and safety regulations under the U.S. Controlled Substances Act.

We implement rigorous internal processes to ensure the quality and safety of our products across their lifecycle – from preclinical studies to commercial use. We purchase our raw materials from suppliers assessed and approved by our Quality team. We carry out in-house testing of raw materials prior to use to confirm they meet our quality standards, and we audit and assess our external manufacturing partners to monitor their compliance with Alkermes standards of quality and with applicable laws and regulations as set forth in more detail below. We also carry out in-house testing of all drug product that we manufacture prior to its release to ensure it meets our quality and compliance requirements.

In addition, the FDA, the European Medicines Agency (EMA) and other global regulatory agencies routinely inspect our facilities in Athlone, Waltham and Wilmington to confirm and certify our compliance with applicable regulatory requirements. To date, all such regulatory inspections have been completed successfully, with no “significant findings.” FDA inspections of Alkermes sites in the past 5 years have all been classified as “No Action Indicated.”

The Alkermes Quality Manual lays out the various principles of quality that are required to be upheld by Alkermes employees and provides guidance for adherence to applicable quality requirements. As part of our QMS, Alkermes employees also receive comprehensive training on the safety and quality resources and standard procedures that we have in place to help ensure our high standards of quality and safety are part of day-to-day operations. Employees are required to train on all new or updated procedures required for their role. Electronic learning systems are used to monitor and manage each employee’s compliance with our training curriculum. Training curricula are developed to specifically match each employee’s role. Depending on the complexity of an employee’s role and the required training for such role, classroom and/or supervised on-the-job training is also provided as needed. We maintain and continually assess, modify and improve our QMS through management’s oversight of the system and through our established quality procedures, including internal audits, external audits, risk assessments, quality performance metrics, corrective actions and preventive actions.

Responsibility in the Supply Chain

Beyond our own facilities, we contract with a growing network of third-party manufacturers to formulate certain products and produce components of products or product packaging for clinical and commercial use. All service providers involved in the manufacture and packaging of our products, or components of our products, are subject to inspection by the FDA or comparable agencies in other jurisdictions, and we require that our contract manufacturers adhere to current GMP in the manufacture of these products and product components. Alkermes Quality personnel audit all of our contract manufacturers and suppliers to assess their compliance with applicable standards and regulations prior to initiating work for Alkermes. We have quality agreements in place with our key suppliers that set forth our quality requirements and procedures and govern monitoring of and compliance with such requirements and applicable laws and regulations. We routinely review, assess and update our requirements, as appropriate, based on new or emerging risks identified, and revise our quality agreements accordingly. Strategic supply chain partners are also informed of and expected to comply with Alkermes EHSS standards and expectations.

If a vendor does not meet our EHSS or quality expectations, we either work with that vendor to improve its adherence prior to working with such vendor or consider alternative vendors.

Responsible Marketing

Sales and Marketing Practices

Alkermes’ Healthcare Compliance Program, which reflects the Department of Health and Human Services’ Office of Inspector General’s seven elements of an effective compliance program, encompasses a series of coordinated, proactive efforts to create, propagate and enforce a culture of compliance designed to ensure that our interactions with those who use our products are consistent with applicable laws, regulations and guidelines.

This program is based on the following principles:

Interactions with customers are focused on education as to the benefits and risks of our products in order to help advance their appropriate use. Interactions with customers must occur in a venue conducive to education and Alkermes prohibits the provision of entertainment to its customers.Promotional communications must be truthful, not misleading, fairly balanced with appropriate safety information, and consistent with the product’s label.Employees are prohibited from using items of value or inkind services to reward or induce a healthcare professional to utilize, prescribe, purchase or recommend our products.The hiring of healthcare professionals as speakers or consultants must be based on a legitimate business need and free from inappropriate influences, and any fees paid to healthcare professionals may not exceed fair market value of the service being provided.

Patient Safety

We are committed to ensuring the authenticity of our medicines and guarding against counterfeit products (those not equivalent in quality, safety and efficacy, or not containing the correct amount of active ingredient and/or containing impurities) in the marketplace in order to protect patients who use our medicines. Alkermes has established a standard operating procedure (SOP) in accordance with FDA regulations that provides for the timely and efficient removal from the market of any commercial drug product suspected or found to be defective. This SOP covers all products – including trade products, sample products and clinical supplies of product candidates – manufactured and distributed by or on behalf of Alkermes. It also includes requirements for the notification of and consultation with applicable regulatory authorities, the conduct of a health hazard assessment, and communications to customers, partners, healthcare professionals and patients as directed by regulators or our internal policies or procedures.

Read more

Originally published in Alkermes September 2023 Corporate Responsibility Report

Ethics and Compliance

Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regulatory and ethical standards in the markets in which we operate and to maintaining a strong culture of compliance.

Our focus on compliance applies to all aspects of our business, beginning with preclinical research and continuing through clinical trials, manufacturing and commercialization. This focus on compliance helps to build trust with healthcare professionals, institutional purchasers, relevant government agencies and the public at large.

Compliance is a responsibility shared by all employees across all levels of the Company. We expect each employee to take an active role in supporting our culture of compliance and to perform all activities and conduct all interactions with integrity and in accordance with the highest ethical standards.

Our commitment to compliance is embodied in our comprehensive compliance program which is built on the following core elements:

Written policies and procedures that address the compliance risk areas relevant to pharmaceutical manufacturers, including those identified in the guidance of the Office of Inspector General of the U.S. Department of Health & Human Services (HHS) and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals.The Company’s Chief Compliance Officer oversees our compliance program and reports directly to the Company’s CEO. The Company’s Corporate Compliance Committee helps oversee the Company’s compliance program and assists with identifying any compliance issues that may need to be brought to the attention of the Board.Alkermes conducts extensive training and education programs for all employees that begin with new hire training and include regular, ongoing training on topics, processes and policies relevant to their positions.Alkermes has established and continues to foster a culture of compliance that maintains effective lines of communication and encourages all employees to seek guidance on ethical or legal issues as they arise. This culture of compliance is further supported by a policy obligating employees to report possible compliance violations and a strong anti-retaliation policy (discussed below) that protects personnel who report issues in good faith.Regular monitoring and auditing of the compliance program enables Alkermes to detect and prevent potential non-compliance.The Company’s policies and training ensure that all employees, including management, are informed of the consequences of failing to adhere to our compliance policies.Our compliance program is designed to promptly respond to and address, through corrective action, any detected instances of non-compliance.

Code of Conduct

Our Code of Business Conduct and Ethics (Code of Conduct) applies to all employees, officers and directors of the Company. A current copy of the Code of Conduct is available on the Corporate Governance page of the Investors section of our website.

Among other things, the Code of Conduct requires:

Honest and ethical conduct by employees, officers and directors of the Company, including the ethical handling of actual, potential or apparent conflicts of interest;Full, fair and understandable disclosure of the Company’s activities in reports filed with the SEC and in the Company’s other public communications; andPrompt internal reporting of any violations of the Code of Conduct to a supervisor, the Company’s Chief Legal Officer or the Company’s Chief Compliance Officer (which role is currently held by the Company’s Chief Legal Officer).

The Code of Conduct also requires compliance with all applicable laws, rules and regulations including, but not limited to, those guiding our interactions with government officials and health care providers. In this context, the Code of Conduct expressly prohibits any bribes, kickbacks or other improper payments, transfers or receipts.

Our employees are obligated to raise concerns about any violations of our Code of Conduct or any other ethics or conduct violations with their supervisor, the Company’s Chief Legal Officer or Chief Compliance Officer, the Audit and Risk Committee of the Board and/or the Nominating and Corporate Governance Committee of the Board or through the Company’s Corporate Governance hotline set forth in the Company’s Procedures for Reporting Financial and Compliance Matters; No Retaliation Policy (Whistleblower Policy). A current copy of the Whistleblower Policy is available on the Corporate Governance page of the Investors section of our website.

Responsible Research 

Clinical Trials

As a patient-focused organization, we value the patients who choose to participate in clinical trials and maintain policies, procedures and practices that are respectful of each study participant and designed to protect their health, safety and well-being. We ensure that our clinical programs comply with the laws and regulations of the jurisdictions where we conduct clinical research, including appropriate informed consent processes, ongoing assessment of patient safety and timely reporting of adverse events, accurate collection and integrity of data and respect for patient confidentiality and privacy.

Ethical Treatment of Animals

Alkermes is committed to the ethical and responsible treatment of animals involved in the Company’s research and development programs. We follow defined practices and standards for the care, welfare and treatment of research animals, as monitored by our Institutional Animal Care and Use Committee; and conduct all animal research in compliance with applicable local, national or international laws such as those set forth in the National Research Council’s Guide for the Care and Use of Laboratory Animals. We also require – through inclusion of relevant provisions in our contractual agreements – that the CROs, academic institutions and animal vendors with whom we engage commit to adherence to these same standards.

Responsible Manufacturing: Product Quality and Safety

Alkermes has robust policies and procedures in place to promote safe and sustainable research, development, manufacture and commercialization of products. We are committed to meeting our manufacturing objectives reliably and responsibly through the establishment and maintenance of a safe, sustainable and ethical supply chain.

Product Quality

The Alkermes Quality Management System (QMS) is a comprehensive program designed to ensure that products manufactured, stored, tested or distributed by Alkermes consistently meet applicable product specifications, safety and efficacy standards, GxP (as defined below) “good practice” quality guidelines and regulations, and regulatory requirements. The QMS is a combination of multiple wellintegrated components, covering the entire lifecycle of the products that we manufacture from development to commercialization and the full supply chain associated with each stage in a product’s manufacture.

Our QMS is designed to ensure compliance with applicable provisions of the U.S. Code of Federal Regulations, ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guidance, the European Commission Directives relating to medicinal products for human use and all aspects of “good practice” quality guidelines and regulations (known collectively as GxP), in each case in line with current industry standards.

GxP includes Good Clinical Practice (GCP) regulations, which govern the conduct of clinical trials, Good Manufacturing Practice (GMP) regulations, which govern the manufacture of products, and Good Laboratory Practice (GLP) regulations, which govern the testing of materials in accordance with applicable regulations. We also adhere to applicable quality and safety regulations under the U.S. Controlled Substances Act.

We implement rigorous internal processes to ensure the quality and safety of our products across their lifecycle – from preclinical studies to commercial use. We purchase our raw materials from suppliers assessed and approved by our Quality team. We carry out in-house testing of raw materials prior to use to confirm they meet our quality standards, and we audit and assess our external manufacturing partners to monitor their compliance with Alkermes standards of quality and with applicable laws and regulations as set forth in more detail below. We also carry out in-house testing of all drug product that we manufacture prior to its release to ensure it meets our quality and compliance requirements.

In addition, the FDA, the European Medicines Agency (EMA) and other global regulatory agencies routinely inspect our facilities in Athlone, Waltham and Wilmington to confirm and certify our compliance with applicable regulatory requirements. To date, all such regulatory inspections have been completed successfully, with no “significant findings.” FDA inspections of Alkermes sites in the past 5 years have all been classified as “No Action Indicated.”

The Alkermes Quality Manual lays out the various principles of quality that are required to be upheld by Alkermes employees and provides guidance for adherence to applicable quality requirements. As part of our QMS, Alkermes employees also receive comprehensive training on the safety and quality resources and standard procedures that we have in place to help ensure our high standards of quality and safety are part of day-to-day operations. Employees are required to train on all new or updated procedures required for their role. Electronic learning systems are used to monitor and manage each employee’s compliance with our training curriculum. Training curricula are developed to specifically match each employee’s role. Depending on the complexity of an employee’s role and the required training for such role, classroom and/or supervised on-the-job training is also provided as needed. We maintain and continually assess, modify and improve our QMS through management’s oversight of the system and through our established quality procedures, including internal audits, external audits, risk assessments, quality performance metrics, corrective actions and preventive actions.

Responsibility in the Supply Chain

Beyond our own facilities, we contract with a growing network of third-party manufacturers to formulate certain products and produce components of products or product packaging for clinical and commercial use. All service providers involved in the manufacture and packaging of our products, or components of our products, are subject to inspection by the FDA or comparable agencies in other jurisdictions, and we require that our contract manufacturers adhere to current GMP in the manufacture of these products and product components. Alkermes Quality personnel audit all of our contract manufacturers and suppliers to assess their compliance with applicable standards and regulations prior to initiating work for Alkermes. We have quality agreements in place with our key suppliers that set forth our quality requirements and procedures and govern monitoring of and compliance with such requirements and applicable laws and regulations. We routinely review, assess and update our requirements, as appropriate, based on new or emerging risks identified, and revise our quality agreements accordingly. Strategic supply chain partners are also informed of and expected to comply with Alkermes EHSS standards and expectations.

If a vendor does not meet our EHSS or quality expectations, we either work with that vendor to improve its adherence prior to working with such vendor or consider alternative vendors.

Responsible Marketing

Sales and Marketing Practices

Alkermes’ Healthcare Compliance Program, which reflects the Department of Health and Human Services’ Office of Inspector General’s seven elements of an effective compliance program, encompasses a series of coordinated, proactive efforts to create, propagate and enforce a culture of compliance designed to ensure that our interactions with those who use our products are consistent with applicable laws, regulations and guidelines.

This program is based on the following principles:

Interactions with customers are focused on education as to the benefits and risks of our products in order to help advance their appropriate use. Interactions with customers must occur in a venue conducive to education and Alkermes prohibits the provision of entertainment to its customers.Promotional communications must be truthful, not misleading, fairly balanced with appropriate safety information, and consistent with the product’s label.Employees are prohibited from using items of value or inkind services to reward or induce a healthcare professional to utilize, prescribe, purchase or recommend our products.The hiring of healthcare professionals as speakers or consultants must be based on a legitimate business need and free from inappropriate influences, and any fees paid to healthcare professionals may not exceed fair market value of the service being provided.

Patient Safety

We are committed to ensuring the authenticity of our medicines and guarding against counterfeit products (those not equivalent in quality, safety and efficacy, or not containing the correct amount of active ingredient and/or containing impurities) in the marketplace in order to protect patients who use our medicines. Alkermes has established a standard operating procedure (SOP) in accordance with FDA regulations that provides for the timely and efficient removal from the market of any commercial drug product suspected or found to be defective. This SOP covers all products – including trade products, sample products and clinical supplies of product candidates – manufactured and distributed by or on behalf of Alkermes. It also includes requirements for the notification of and consultation with applicable regulatory authorities, the conduct of a health hazard assessment, and communications to customers, partners, healthcare professionals and patients as directed by regulators or our internal policies or procedures.

Read more

What started as a “pizza garden” has grown into one of the Boys & Girls Club of the Bemidji Area’s signature programs—improving the wellbeing of youth through horticulture, healthy eating and entrepreneurship.

In 2005, participants in the northern Minnesota Club planted, tended and harvested their favorite pizza toppings in a single raised garden bed.

Along with the peppers, basil and onions, the concept sprouted and blossomed. Over 18 years, it has evolved into a full-scale gardening program with 20 raised beds, four hydroponic units, a 1,500 square-foot grow tunnel, 2,000 square feet of pavers, and an outdoor education center.

“Our kids love it, our families love it, and our community loves it,” says Shelby Weckwerth, the Club’s grant director, of the gardening program.

“We grow close to 50 different types of produce every year—purple carrots and purple peppers and all the different colors,” she explains. “Families express that a lot of our Club members start their own gardens at home because they’re inspired by what they do here.”

The programming doesn’t stop after cultivation. Once a week, for example, a local culinary chef and restaurateur teaches the kids to cook nutritious meals.

Participants can literally dine on the fruits of their labor in Bemidji Area School District cafeterias, which includes the youth-grown produce in salad bars under signage that it was “grown by Boys & Girls Club members.”

And, during the harvest season, the youth hold market nights to sell what they’ve grown to their families at low prices. The budding gardeners become student entrepreneurs; they handle advertising, merchandizing and venue setup, and are responsible for customer service and financial transactions.

“It’s one of my personal favorite experiences to watch the whole program come to fruition at these farmer’s markets,” Weckwerth adds.

Like all Boys & Girls Clubs, the Bemidji chapter is its own non-profit organization. Funding for all of its programs, including the garden, comes from donations from the community and grants.

Enbridge is committed to building vibrant and sustainable communities near our operations, and a recent $2,500 Fueling Futures grant has supported the Club’s garden program this year.

One of our commitments as a company is to help develop the potential of youth; the garden program does so in myriad ways. It teaches them gardening and good nutrition, increases their access to fresh food, provides regular physical activity outdoors, and introduces them to entrepreneurial activities.

The program’s benefits are tangible, not only in the produce grown by the youths’ care and effort, but also at the harvest celebration, a yearly dinner held to recognize the young gardeners who participate in the program.

Each participant gets the opportunity to address the crowd and share a notable moment from the season—their favorite fruit or vegetable, how to care for a certain type of plant, a memory they’ll cherish.

The message is clear. Time spent in the garden—hands in soil, time spent tending and nurturing greenery—takes root in the hearts and minds of youth, anchoring them in a space of health, happiness and wellbeing.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.